Structural insights into drug development strategy targeting EGFR T790M/C797S
Authors:
Open Access
- 10 January 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (17) , 13652-13665
Abstract
Structural insights into drug development strategy targeting EGFR T790M/C797S Structural insights into drug development strategy targeting EGFR T790M/C797SKeywords
This publication has 38 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences, 2008
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityCancer Cell, 2007
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorCell, 2006
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004